SGEN - Seattle Genetics, Inc.
| Previous Close | 60.94 |
| Open | 61.70 |
| Bid | 61.80 x 1000 |
| Ask | 61.97 x 1100 |
| Day's Range | 61.08 - 62.74 |
| 52 Week Range | 47.75 - 84.37 |
| Volume | 224,179 |
| Avg. Volume | 1,171,403 |
| Market Cap | 9.902B |
| Beta (3Y Monthly) | 2.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.06 |
| Earnings Date | Feb 4, 2019 - Feb 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.36 |
Market Realist•23 hours agoUnderstanding Seattle Genetics’ Operational Performance
How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.
Market Realist•23 hours agoWhat Seattle Genetics’ Bottom-Line Trend Indicates
Seattle Genetics (SGEN) had generated net investment and other income of $82.22 million in the third quarter of 2017. In the third quarter of 2018, on the other hand, it incurred net investment and other loss of $21.87 million.
Market Realist•23 hours agoHow’s Seattle Genetics Positioned?
How's Seattle Genetics Positioned? Seattle Genetics (SGEN) is a biotechnology company with a focus on developing and bringing to market targeted therapies for cancer. Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
- GlobeNewswire•2 days ago
Report: Developing Opportunities within Covanta Holding, Zscaler, Avaya, Seattle Genetics, Viad, and Canada Goose — Future Expectations, Projections Moving into 2019
NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Markit•4 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
Markit•8 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Business Wire•9 days ago
Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Data Presented in Oral Session with Simultaneous Publication in The Lancet-
- Business Wire•10 days ago
Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting
-Data Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma-
- Business Wire•11 days ago
Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting
-Initial Data Reported from Phase 2 Clinical Trial in Relapsed Primary Mediastinal Large B-Cell Lymphoma-
- American City Business Journals•12 days ago
Seattle Genetics opening Bay Area office to attract talent it can't lure to Bothell
It's the Bothell-based company's first U.S. office outside the Puget Sound region and may be a stepping stone to further expansion around the country.
Markit•13 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Business Wire•16 days ago
Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
Seattle Genetics, Inc. announced today that the company will webcast an investor and analyst event on Monday, December 3, 2018 during the 60th American Society of Hematology Annual Meeting in San Diego, Calif. The program will feature the phase 3 ECHELON-2 trial as well as other key data from the meeting.
Markit•18 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Simply Wall St.•22 days ago
What You Must Know About Seattle Genetics Inc’s (NASDAQ:SGEN) Financial Health
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Seattle Genetics Inc (NASDAQ:SGEN), with a market capitalization of US$9.2b, rarely draw their attention from the investing Read More...
- Zacks•23 days ago
Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session
Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 6% on Friday, amid huge volumes.
- ACCESSWIRE•23 days ago
Today's Research Reports on Trending Tickers: Amarin and Seattle Genetics
NEW YORK, NY / ACCESSWIRE / November 19, 2018 / U.S. equities finished mostly in the green on Friday as investors digested comments from President Donald Trump, expressing confidence in resolving the current ...
- MarketWatch•26 days ago
Seattle Genetics stock jumps 6% after new FDA approval for lymphoma treatment
Shares of Seattle Genetics Inc. rose more than 6% Friday, after the company said it had received a new approval for its Adcetris therapy as a treatment for previously untreated peripheral T-Cell Lymphoma. The U.S. Food and Drug Administration approved Adcetris in combination with CHP chemotherapy based on the successful outcome of its phase 3 ECHELON-2 clinical trial, the company said in a statement. The FDA used a new approval pathway that allowed it to come just two weeks after the company submitted data and just under two months since it announced topline data. "While this approval was widely anticipated given the Overall Survival benefit and positive trial (ECHELON-2), we believe SGEN shares will react favorably given that it suggests PTCL revenues are likely to start in Q4, and also dispels any risk from the upcoming American Society of Hematology (ASH) presentation, especially in regards to the broader, non-ALCL (anaplastic large cell lymphoma ) cohort, which were included in this label," said Leerink analyst Andrew Berens. Leerink was previously expected revenue to start in 2019. It is the sixth FDA-approved indication for Adcetris. Shares have gained 7% in 2018, while the S&P 500 has gained 2%.
- Business Wire•26 days ago
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
-First FDA-Approved Regimen in Frontline Peripheral T-Cell Lymphoma-
- Zacks•26 days ago
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.
- Business Wire•27 days ago
FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
-Designation Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphomas; Data to be Presented at Upcoming American Socie
- Business Wire•28 days ago
Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma
-SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma-
Markit•last monthSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Seattle Genetics
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
- Business Wire•last month
Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference
Seattle Genetics, Inc. announced today that management will present at the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018 at 2:15 p.m. Mountain Time.
- Business Wire•last month
Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Submission Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphoma-
